【レポートの概要（一部）】
1. Introduction to CD Antigens
2. Nomenclature & Classification of CD Antigens
3. Mechanism of CD Antigen Cancer Therapeutics
4. Cancer CD Antigen Therapy Market Overview
4.1 Current Scenario
4.2 Cancer CD Antigen Inhibitors Pipeline Overview
5. CD Antigen Cancer Market Dynamics
5.1 Favorable Market Parameters
5.2 Commercialization Challenges
6. CD Antigen Cancer Therapeutics Future Prospects
7. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
7.1 Phase-I/II
8. Cancer CD3 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
8.1 Preclinical till Phase-II
9. Cancer CD4 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
9.1 Phase-II
10. Cancer CD9 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
10.1 Preclinical
11. Cancer CD11 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
11.1 Preclinical
12. Cancer CD19 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
12.1 Phase-I till Phase-II
13. Cancer CD20 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
13.1 Research till Phase-III
13.2 Marketed CD20 Antigen Inhibitors Drug Clinical Insight
14. Cancer CD22 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
14.1 Phase-II till Phase-III
15. Cancer CD26 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
15.1 Preclinical till Phase-I/II
16. Cancer CD27 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
16.1 Research till Phase-I/II
17. Cancer CD28 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
17.1 Preclinical
18. Cancer CD29 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
18.1 Preclinical
19. Cancer CD33 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
19.1 Phase-I till Phase-I/II
19.2 Marketed CD33 Antigen Inhibitors Drug Clinical Insight
20. Cancer CD37 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
20.1 Phase-I till Phase-II
21. Cancer CD38 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
21.1 Research till Preregistration
22. Cancer CD40 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
22.1 Phase-I
23. Cancer CD44 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
23.1 Preclinical
24. Cancer CD45 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
24.1 Preclinical till Phase-II
25. Cancer CD47 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
25.1 Preclinical till Phase-I
26. Cancer CD52 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
26.1 Research till Preclinical
26.2 Marketed CD52 Antigen Inhibitors Drug Clinical Insight
27. Cancer CD55 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
27.1 Preclinical till Phase-II
28. Cancer CD56 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
28.1 Preclinical till Phase-II
29. Cancer CD66 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
29.1 Preclinical till Phase-II
30. Cancer CD70 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
30.1 Phase-I
31. Cancer CD74 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
31.1 Preclinical till Phase-I/II
32. Cancer CD80 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
32.1 Preclinical till Phase-II
33. Cancer CD95 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
33.1 Preclinical
34. Cancer CD98 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
34.1 Phase-I
35. Cancer CD100 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
35.1 Phase-I
36. Cancer CD117 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
36.1 Preclinical till Phase-III
36.2 Marketed CD117 Antigen Inhibitors Drug Clinical Insight
37. Cancer CD135 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
37.1 Preclinical till Phase-III
37.2 Marketed CD135 Antigen Inhibitors Drug Clinical Insight
38. Cancer CD137 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
38.1 Preclinical
39. Cancer CD152 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
39.1 Marketed CD152 Antigen Inhibitors Drug Clinical Insight
40. Cancer CD200 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
40.1 Preclinical
41. Cancer CD223 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
41.1 Research till Phase-I
42. Cancer CD227 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
42.1 Phase-I till Phase-II
43. Cancer CD246 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
43.1 Preclinical till Phase-II
43.2 Marketed CD246 Antigen Inhibitors Drug Clinical Insight
44. Cancer CD248 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
44.1 Phase-II
45. Cancer CD274 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
45.1 Research till Phase-III
45.2 Marketed CD274 Antigen Inhibitors Drug Clinical Insight
46. Cancer CD276 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
46.1 Phase-I
47. Cancer CD279 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
47.1 Phase-I till Phase-II
47.2 Marketed CD279 Antigen Inhibitors Drug Clinical Insight
48. Multiple Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
48.1 Preclinical till Phase-III
48.2 Marketed Multiple CD Antigen Inhibitors Drug Clinical Insight
49. Discontinued & Suspended Cancer CD Antigen Inhibitors Drug Clinical Insight
49.1 No Development Reported
49.2 Discontinued
49.3 Market Withdrawal
49.4 Suspended
50. Competitive Landscape
50.1 Alexion Pharmaceuticals
50.2 ARIAD Pharmaceuticals
50.3 AryoGen Biopharma
50.4 AXXO
50.5 Bayer HealthCare
50.6 Biocad
50.7 Biogen
50.8 Biotecnol Inc.
50.9 Bristol-Myers Squibb
50.10 Chugai Pharmaceutical
50.11 Dr Reddy’s Laboratories
50.12 Eisai Co Ltd
50.13 Emergent BioSolutions
50.14 Genmab
50.15 ImmunoGen
50.16 Intas Biopharmaceuticals
50.17 MacroGenics
50.18 MedImmune
50.19 Merck
50.20 Novartis
50.21 Ono Pharmaceutical
50.22 Onyx Pharmaceuticals
50.23 Pfizer
50.24 PROBIOMED
50.25 Roche
50.26 UCB
50.27 Xencor
【レポート販売概要】
■ タイトル：がんCD抗原阻害剤の世界市場及びパイプライン2015■ 英文：Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015
■ 発行日：42217
■ 調査会社：KuicK Research
■ 商品コード：KUIK51101
■ 調査対象地域：グローバル
- 前立腺肥大症の疫学的予測（～2024）EpiCast Report: Benign Prostatic Hyperplasia - Epidemiology Forecast to 2024 Summary Benign prostatic hyperplasia (BPH) is a nonmalignant growth of prostatic tissue that surrounds the urethra, and leads to constriction of the urethral opening, which gives rise to lower urinary tract symptoms (LUTS). BPH is commonly observed in men ages 40 years and above. The diagnosis of BPH is made on clinical b …
- 拡張現実（AR）用ソフトウェアの世界市場予測（～2022年）“Increasing use of AR software in consumer electronics is the major driver for the augmented reality software market”The augmented reality software market was valued at USD 2.13 billion in 2016 and is expected to reach USD 35.22 billion by 2022, growing at a CAGR of 57.36% during the forecast period. The increasing demand for AR-based software applications for 3D visualization in the medical secto …
- M2Mの技術要因、マーケットダイナミクス及び産業（M2M Technology Drivers, Market Dynamics, and Industry Verticals）The M2M ecosystem has gained significant momentum recently, driven largely by necessity as cellular service provider revenue opportunities diminish due to flattening mobile subscriber base growth. Network operators have recognized the need to leverage their substantial investment in infrastructure to offer M2M as a value-added services that will add new sources of revenue. However, growth in M2M i …
- UK Hospital Coagulation Testing Market 2014This new report from Venture Planning Group contains 402 pages, 28 tables, and presents a comprehensive analysis of the UK hospital coagulation testing market, including: Major issues pertaining to the UK coagulation laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Volume and …
- ハイスピードカメラのグローバル市場（2014 – 2020）High speeds cameras are devices used for the slow capture motion of the high speed events and are used in different applications. Strategic focus areas for the key players would be technology innovations and new product developments rather than existing product development; as striving for product differentiation would boost a player ahead in the race, in the current scenario. Focus on industry re …
- 2014年戦略提言：Syphilis診断検査市場The report presents a detailed analysis of the Syphilis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Syphilis definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Comme …
- 世界のおむつ（Diaper）製品市場（2014-2018）TechNavio's analysts forecast the Global Diaper market to grow at a CAGR of 4.36 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increased average disposable income. The Global Diaper market has also been witnessing the increased R&D investments by the vendors. However, the declining birth rates in developed markets could pose a challenge to the …
- 硫酸の世界市場2017-2021About Sulphuric Acid Sulfuric acid is one of the most important industrial chemicals and is used for various applications including fertilizers, chemical production, and metal processing. The global sulfuric acid market is expected to grow at a CAGR of 2.62% during the forecast period. Sulfuric acid finds the largest application in the fertilizer industry for the production of phosphoric acid thro …
- アダルトグッズの世界市場2016-2020About Sex Toys Products that enhance sexual health and experience include condoms, sensual lingerie, lubricants, contraceptives, costumes, accessories, oils, herbal supplements, and sex toys. Sex toys are sexual stimulation devices used to enhance pleasure and create a memorable experience for the user. These toys are quickly gaining prevalence and traction in the market. They are entering the mai …
- 世界の燃料電池市場展望（～2018）The fuel cell industry, which is presently on a nascent stage, presents huge potential for growth in the coming years. Its efficiency created demand for the technology in various application areas including military, electronic devices, transportation, traffic signaling, security and remote monitoring, etc. Also, declining prices of fuel cells and advanced R&D activities are adding growth to the f …
- 屋根用タイルの世界市場：クレイタイル、コンクリートタイルAbout the Roofing Tiles Market A roofing tile provides protection to the structure below from heat and rain. Modern day roofing tiles are available in a variety of shapes and sizes to provide an aesthetic appeal to the overall building. These tiles can be fixed onto the roof through either nails or even cement at select points of the tile. Technavio’s analysts forecast the global thoracic surgery …
- 乾癬性関節炎治療薬の世界市場2015-2019Psoriatic arthritis is a chronic inflammatory disease that affects the distal joints in the body and may also affect the back and sacroiliac joints of the pelvis. The global market for psoriatic arthritis is expected to witness moderate growth during the forecast period and factors like the increase in penetration of biologic therapies are expected to augment the prospects for growth in this marke …
- 教育用ロボットの世界市場2016-2020About the Educational Robots Market The benefits of technology across different industries has led the education industry to become adopt the latest and most-suitable technologies to enhance teaching delivery and learning experience. With advances in technology, robotics has been successfully integrated into various sectors. Industrial robots have replaced the manual workload in many industries wh …
- BYODセキュリティソリューションの世界市場：モバイルデバイス管理（MDM）、モバイルアプリケーション管理（MAM）About BYOD Security Enterprise mobility refers to accessing of corporate data by the employees using their personal devices. Enterprise mobility solutions serve the purpose of keeping the remotely working employees of an organization connected with the company and its data. The solution helps capture, manage, store, and transfer of corporate data through cloud-based services. An organization adopt …
- 自動車用打ち抜き装置の世界市場2018-2022About Automotive Die-stamping Equipment Die-Stamping equipment is a tool that helps in forming the desired shape by means of deformation without the removal of any material. The die-stamping equipment consists of two dies, between which the material required is pressed with appropriate stress to form the desired shape. Technavio’s analysts forecast the global automotive die-stamping equipment mark …
